http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108310125-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-736 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-483 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-286 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-288 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-815 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-84 |
| filingDate | 2018-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108310125-B |
| titleOfInvention | Application of Qianliexin in antithrombotic drugs |
| abstract | The invention discloses an antithrombotic pharmaceutical composition and application thereof, the composition is prepared from active ingredients and auxiliary materials, the active ingredients comprise a Qianliexin water sample, an ethyl ester sample, a petroleum ether sample and an n-butyl alcohol sample, the Qianliexin water sample has a concentration of 30-120 mu g/mL, preferably 120 mu g/mL, the Qianliexin ethyl ester sample has a concentration of 30-60 mu g/mL, preferably 30 mu g/mL, the Qianliexin petroleum ether sample has a concentration of 7.5-30 mu g/mL, preferably 30 mu g/mL, the Qianliexin n-butyl alcohol sample has a concentration of 60-120 mu g/mL, preferably 120 mu g/mL. The medicine of the present invention has strong biological activity of resisting thrombosis, and can be independently used as a medicine for preventing and treating thrombotic diseases. |
| priorityDate | 2018-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.